相关实验视频

Updated: May 22, 2025

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

多基因组识别了与BRAF V600E突变高级固体瘤患者的BRAF向治疗后的结果相关的潜在分子概况

Martina Eriksen¹, Anne M Hansen², Annelaura B Nielsen³

¹Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

JCO precision oncology

|March 13, 2025

概括

转换TP53与BRAF向治疗中的较差结果有关. 多原子分析确定了TP53野生型状态和特定的基因表达特征作为改善治疗反应的潜在生物标志物.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
蛋白质组学是指蛋白质组学.
翻译研究是翻译研究.

背景情况:

针对BRAF的向治疗选择缺乏BRAF V600E.以外的预测生物标志物.
识别新的生物标志物对于个性化癌症治疗至关重要.

研究的目的:

调查基线分子变化和BRAF向治疗结果之间的关联.
探索多原子数据 (基因组,转录组,蛋白质组) 在预测治疗反应中的实用性.

主要方法:

来自哥本哈根前性个性化瘤学研究中的患者新鲜瘤组织的综合分子分析.
分析包括基因组,转录组 (RNAseq) 和蛋白质组概况.
统计分析以将分子变化与无进展生存率相关联.

主要成果:

经常检测到TP53突变,并与明显较短的无进展生存期相关.
在TP53野生型瘤中,一个明显的基因表达特征表明细胞循环停止和p53通路活性.
在长期控制疾病的患者中观察到乌比基结合酶EK2的下调.

结论:

多原子分析确定TP53变异和基因表达特征是BRAF向治疗的潜在预测生物标志物.
这项研究强调了多原子数据在推进精确瘤学的前景.
建议在翻译性癌症研究中优先考虑多组数据分析.

更多相关视频

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...